EMA Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

By: via Benzinga
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.